Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial-Reference-Cited by-同舟云学术

Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial

Published:2017-07 Issue:7 Volume:16 Page:513-522
ISSN:1474-4422
Container-title:The Lancet Neurology
language:en
Short-container-title:The Lancet Neurology

Author:

Bertini Enrico,Dessaud Eric,Mercuri Eugenio,Muntoni Francesco,Kirschner Janbernd,Reid Carol,Lusakowska Anna,Comi Giacomo P,Cuisset Jean-Marie,Abitbol Jean-Louis,Scherrer Bruno,Ducray Patricia Sanwald,Buchbjerg Jeppe,Vianna Eduardo,van der Pol W Ludo,Vuillerot Carole,Blaettler Thomas,Fontoura Paulo,André Carole,Bruno Claudio,Chabrol Brigitte,Deconinck Nicolas,Estournet Brigitte,Fontaine-Carbonnel Stephanie,Goemans Nathalie,Gorni Ksenija,Govoni Alessandra,Guglieri Michela,Lochmuller Hanns,Magri Francesca,Mayer Michele,Müller-Felber Wolfgang,Rivier François,Roper Helen,Schara Ulrike,Scoto Mariacristina,van den Berg Leonard,Vita Giuseppe,Walter Maggie C

Publisher

Elsevier BV

Subject

Neurology (clinical)

Reference27 articles.

1. Spinal muscular atrophy;Lunn;Lancet,2008

2. The neurobiology of childhood spinal muscular atrophy;Crawford;Neurobiol Dis,1996

3. Understanding the experiences and needs of individuals with Spinal Muscular Atrophy and their parents: a qualitative study;Qian;BMC Neurol,2015

4. Correlation between severity and SMN protein level in spinal muscular atrophy;Lefebvre;Nat Genet,1997

5. Mitochondrial dysfunction in a neural cell model of spinal muscular atrophy;Acsadi;J Neurosci Res,2009

Cited by 99 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The mitochondrial translocator protein (TSPO) in Alzheimer's disease: Therapeutic and immunomodulatory functions;Biochimie;2024-09

2. Long-term impact of nusinersen on motor and electrophysiological outcomes in adolescent and adult spinal muscular atrophy: insights from a multicenter retrospective study;Journal of Neurology;2024-07-19

3. Estimating treatment effect in randomized trial after control to treatment crossover using external controls;Journal of Biopharmaceutical Statistics;2024-04

4. Emerging Gene Therapy Approaches in the Management of Spinal Muscular Atrophy (SMA): An Overview of Clinical Trials and Patent Landscape;International Journal of Molecular Sciences;2023-09-06

5. Mitochondrial creatine sensitivity is lost in the D2.mdx model of Duchenne muscular dystrophy and rescued by the mitochondrial-enhancing compound Olesoxime;American Journal of Physiology-Cell Physiology;2023-05-01